Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16049737 | 0.84 | USP2 (0.41) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL15475694 | 0.83 | USP2 (0.43) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL26104381 | 0.82 | USP2 (0.35) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL23123884 | 0.81 | CTSK (0.34) | NR1H2CTSK | |
| SCHEMBL31574926 | 0.81 | USP2 (0.37) | USP2SMN1; SMN2DDB1CRBNGPR119 | |
| SCHEMBL13531077 | 0.81 | USP2 (0.43) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL1224512 | 0.80 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL31511515 | 0.80 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL16433062 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL2129847 | 0.79 | USP2 (0.44) | USP2SMN1; SMN2DDB1CRBNNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| WO-2022267495-A1 | NITROGEN-CONTAINING OXA-SPIROCYCLIC COMPOUND AND USE THEREOF | 南昌弘益药业有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3851440-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | Medshine Discovery Inc. (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020052649-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | 南京明德新药研发有限公司 | 2020-03-19 | — | — | WO | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1286967-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2001087838-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | USP2 1839/4885SMN1; SMN2 1440/4885DDB1 116/4885 |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | USP2 4091/4885SMN1; SMN2 3052/4885DDB1 1737/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | USP2 1819/4885SMN1; SMN2 1656/4885DDB1 133/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | USP2 1839/4885SMN1; SMN2 1440/4885DDB1 116/4885 |
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | KDM1B, KDM1A, KDM7A | USP2 516/4885SMN1; SMN2 1937/4885DDB1 1865/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | USP2 1610/4885SMN1; SMN2 1713/4885DDB1 246/4885 |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | KDM1B, KDM1A, KDM7A | USP2 516/4885SMN1; SMN2 1937/4885DDB1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.